Unveiling Diagnostic Biomarkers in High-Grade Serous Ovarian Cancer Through Bioinformatics Analysis

Aicha Lakhssassi,Alsamman Alsamman,Manar Samir Abdullah Ibrahim,Naima Nourouti,Amina Barakat,Mohcine Mechita,Joaira Bakkach
DOI: https://doi.org/10.1200/go-24-14900
2024-07-01
JCO Global Oncology
Abstract:PURPOSE Ovarian cancer stands out among the most lethal gynecological malignancies worldwide, displaying a low survival rate, particularly alarming at stage IV, with only approximately 15% 5 years survival rate. Moreover, two-thirds of deaths attributable to ovarian cancer are specifically associated with high-grade serous ovarian cancer. The objective of the present study is to identify new biomarkers specific to the high grade serous ovarian carcinoma subtype using a bioinformatics approach. METHODS Two gene expression profiles of ovarian tissues and corresponding clinical data were downloaded from the GEO database. The second dataset was used to improve the accuracy of the analysis and find key hub genes that are solely specific for the high-grade serous carcinoma. Protein-Protein Interaction (PPI) network was systematically conducted. The mRNA sequencing (RNA-seq) data of both tumor and normal ovarian tissues was analyzed using R. Statistical significance was determined based on an adjusted p-value of less than 0.05. PPI network was visualized by cytoscape using Cytohubba plugin. RESULTS Altogether, 1290 genes were identified as differentially expressed genes (DEGs) between the two datasets, with 915 genes showing significant upregulation and 375 genes displaying significant downregulation. CRABP1 and SLCO6A1 were notably highly expressed in both datasets, exhibiting a fold change greater than 7. These genes displayed intriguing interactions with CDKN2A, CCNA2, CDC6, CDK1, CDC25C and AURKB which are known to have connection to the cell cycle pathway, and thus emphasizing their potential role in regulating cell division and proliferation. CONCLUSION Collectively, our study identifies dysregulated genes that would serve as novel potential biomarkers for high grade serous ovarian cancer and ultimately help us find novel cancer therapeutic targets. Validation through experimental assays and clinical studies will be necessary to confirm the functional significance and clinical relevance of these identified biomarkers.
What problem does this paper attempt to address?